Bad trial design faulted for GW's Phase III failure

Blindsided by a big placebo effect, GW Pharma says its lead therapy Sativex for pain narrowly missed hitting the goal of statistically significant improvement for patients with multiple sclerosis. The news ripped right into the company's stock price, with shares plunging more than 20 percent after the numbers were released. Half of the patients in the trial reported a 30 percent reduction in pain, but so did about 45 percent of the placebo group.

The trial design may be the primary culprit, points out The Times. Volunteers were allowed unlimited access to under-the-tongue spray, allowing the placebo group easy access to an alternative therapy. Sativex, a therapy derived from cannabis, will now be studied for MS spasticity and cancer pain.

- see the release
- read the report from Hemscott
- and check out the story from The Times

Related Articles:
GW inks $273M deal for Sativex. Report
FDA approves late-stage Sativex study as GW seeks partner. Report
New Sativex trial planned. Report
Sativex faces more delays. Report

Suggested Articles

Bluebird Bio offered the first glimpse of how its CAR-T follow-up is working in multiple myeloma patients who have tried several other treatments.

Zentalis is coming out of stealth with an $85 million series C, which will propel its lead programs into pivotal trials and broaden its pipeline.

The planned takeover centers on ARQ 531, a BTK inhibitor that triggered durable responses in patients with B-cell malignancies.